Campaigners stage a protest in Dublin city centre calling on Ireland’s Health Service Executive (HSE) to approve reimbursement for Skyclarys, a treatment for Friedreich’s Ataxia. Organisers say the demonstration is aimed at influencing the HSE’s final decision process and pressing for access to the drug.
Both reports describe a public show of support for patients and families affected by the rare neurological condition. RTE News frames the event as a “final push” ahead of the HSE’s approval outcome, while the Irish Examiner highlights that the protest comes as a deadline for the final decision approaches.
While the outlets differ in emphasis—one focusing on timing as a final effort, the other on the scale of participation and the looming decision date—both point to the same core issue: campaigners want Skyclarys reimbursed so it can be funded for patients in Ireland.
